University Health Network
Impact of clonal hematopoiesis in donors on allogeneic hematopoietic stem cell transplantation outcomes
Allogeneic hematopoietic stem cell transplant still remains the only curative treatment modality in many of hematologic malignancy treatment. It requires transfer of hematopoietic stem cells from healthy donor to the recipient, i.e. patient with hematologic malignancy. Suitable donors may be matched related donor followed by matched unrelated individuals or half matched family members. As donors themselves may have abnormalities of their blood forming cells called clonal hematopoiesis, it is important that we should be able to identify the most appropriate donor incorporating this information in donor selection. Incorporating this novel genomic information from donors together, we can develop a new recommendation on donor selection process for allogeneic stem cell transplantation.